Advertisement
Mr. Edwin Marshall, Chairman and CEO of Medizone International stated,"With Dr. Shannon's leadership in this exciting new initiative, we anticipatebeing fully commercialized within 18 months. The anticipated revenue generatedwill fund advanced efforts in developing bio-terrorism counter-measures, anarea of enormous potential for this technology, as well as funding a new focuson our work in the treatment of Hepatitis C."
Advertisement
Medizone International, Inc., is a research and development stage companyengaged in the development of patented and unpatented technologies andprotocols for O3 based bio-oxidative treatment of diseases caused by lipidenveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS),Hepatitis B & C, and Herpes, the decontamination of blood, blood products andveterinarian serum products, and the treatment of external pathogenicconditions. It is currently developing technology to decontaminate andsterilize hospital surgical suites, emergency rooms and intensive care units.
This Press Release contains certain forward looking statements thatinvolve substantial risks and uncertainties, including, but not limited to,the results of ongoing clinical studies, economic conditions, product andtechnology development, production efficiencies, product demand, competitiveproducts, competitive environment, successful testing and governmentregulatory issues. Additional risks are identified in the company's filingsmade with the Securities and Exchange Commission.Web site: http://www.medizoneint.com Investor Relations 800-953-3350
SOURCE Medizone International, Inc.